Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces Cerevisiae CNCM I-3856 in IBS-D and PI-IBS
NCT00977587Phase 2Withdrawn
- Sponsor
- University of Nottingham
- Start
- Jan 2011
- Primary completion
- Jan 2012
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome (IBS), Post-infectious irritable bowel syndrome (PI-IBS), sponsored by University of Nottingham. Planned start Jan 2011; status: withdrawn.
02
Drugs
saccharomyces cerevisiae CNCM I-3856
03
Conditions
irritable bowel syndrome (IBS)Post-infectious irritable bowel syndrome (PI-IBS)
Beyond the preview
Go deeper on NCT00977587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977587.